BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.

doi:10.1016/j.annonc.2025.05.534

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Oct 2025

Olmos D, Lorente D, Jambrina A, Tello-Velasco D, Ovejero-Sánchez M, Gonzalez-Ginel I, Romero-Laorden N, Nunes-Carneiro D, Balongo M, Gutierrez-Pecharromán A M, Llácer C, Prieto J D, Pérez-Argüelles D, Alberca Del Arco F, Miguel-Masiá J, Ruiz-Vico M, Santos R, Esteban-Villarrubia J, Gonzalez-Billalabeitia E, Jürgens A, Capone C, Trevisan M, Van Sanden S, Stulnig G, Hernández D, López-Casas P P, Rodriguez-Antolin A, Castellano D E, Herrera-Imbroda B, Castro E

Abstract excerpt

BACKGROUND: Alterations in BRCA1/2 (BRCA) and other homologous recombination repair (HRR) genes have a negative impact on outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC). Poly(adenosine diphosphate-ribose) polymerase inhibitors, the only treatment demonstrated to improve the prognosis of patients with mCRPC, are also being developed for the treatment of patients with metastatic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Prevalence

Share to Prognosis

Share to Prostatic Neoplasms, Castration-Resistant

Share to Recombinational DNA Repair

Source

Open in PubMed

Identifiers

PMID: 40467032
DOI: 10.1016/j.annonc.2025.05.534

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomes.PMID 40467032Read ↗

Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations.Semantic proximity Read ↗

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Semantic proximity Read ↗

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerSemantic proximity Read ↗

Impact of mutations in homologous recombination repair genes on treatment outcomes for metastatic castration resistant prostate cancer.Semantic proximity Read ↗

Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes.Semantic proximity Read ↗

Genomic characterization of metastatic castration‐resistant prostate cancer patients undergoing PSMA radioligand therapy: A single‐center experienceSemantic proximity Read ↗

Impact of homologous recombination repair gene mutations on survival in metastatic prostate cancer: A real-world analysis from an observational database.Semantic proximity Read ↗

Real-world data on the prevalence of BRCA1/2 and HRR gene mutations in patients with primary and metastatic castration resistant prostate cancer.Semantic proximity Read ↗

Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2)Semantic proximity Read ↗

Genomic Determinants of Lethality and Therapeutic Vulnerability in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Homologous Recombination Repair Mutations, Next-generation Sequencing Testing, and Treatment Progression by Race Among Patients With Metastatic Castration-sensitive Prostate Cancer.Semantic proximity Read ↗

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.